GlaxoSmithKline
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults
Phase 3
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: RSVPreF3 OA investigational vaccineBiological: PCV20
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1113
- Registration Number
- NCT05879107
- Locations
- πͺπΈ
GSK Investigational Site, Valencia, Spain
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Phase 2
Recruiting
- Conditions
- Scleroderma, SystemicSystemic Sclerosis Associated Interstitial Lung Disease
- Interventions
- Other: PlaceboBiological: Belimumab
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT05878717
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Phase 3
Recruiting
- Conditions
- Neoplasms, ColonColonic Neoplasms
- Interventions
- Drug: CAPEOXBiological: DostarlimabDrug: FOLFOX
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 711
- Registration Number
- NCT05855200
- Locations
- π¬π§
GSK Investigational Site, Sutton, United Kingdom
A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain
Phase 2
Active, not recruiting
- Conditions
- PainOsteoarthritis, Knee
- Interventions
- Drug: GSK3858279Drug: Placebo
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 314
- Registration Number
- NCT05838742
- Locations
- π¬π§
GSK Investigational Site, Norwich, United Kingdom
A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain
Phase 2
Active, not recruiting
- Conditions
- Pain
- Interventions
- Drug: PlaceboDrug: GSK3858279
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 145
- Registration Number
- NCT05838755
- Locations
- π¬π§
GSK Investigational Site, Wrexham, United Kingdom
A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
Phase 1
Active, not recruiting
- Conditions
- Influenza, Human
- Interventions
- Biological: Flu mRNACombination Product: Control 1Combination Product: Control 2
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1256
- Registration Number
- NCT05823974
- Locations
- πΏπ¦
GSK Investigational Site, East London, South Africa
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
Not yet recruiting
- Conditions
- Herpes Zoster
- Interventions
- Other: Data collection
- First Posted Date
- 2023-04-13
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2844
- Registration Number
- NCT05811754
Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT05791565
- Locations
- π³π±
GSK Investigational Site, Groningen, Netherlands
Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 27
- Registration Number
- NCT05760261
- Locations
- π¬π§
GSK Investigational Site, Cambridge, United Kingdom
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
Phase 3
Recruiting
- Conditions
- Asthma
- Interventions
- Drug: FF/UMEC/VIDevice: ELLIPTADrug: FF/VI
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 292
- Registration Number
- NCT05757102
- Locations
- πΉπ·
GSK Investigational Site, Konyaalti, Turkey
Β© Copyright 2025. All Rights Reserved by MedPath